Delaying second dose of COVID-19 vaccine under 65 reduces mortality: study

New York, May 13: A team of U.S. researchers has found that delaying the second dose of the COVID-19 vaccine can lead to death in up to 20 percent of people under the age of 65, but only under certain conditions.

A study published by BMJ found that 80 per cent or more of these conditions include a single dose of vaccine efficacy (efficacy) and vaccination rates ranging from 0.1 per cent to 0.3 per cent of the population per day.

The study noted that if these conditions apply, the strategy could prevent 47 to 26 deaths per 100,000 people, respectively. Increase the interval between two sizes of the goviShield to 12-16 weeks: Government Board

“Decision-makers should consider their local vaccine rates and weigh the benefits of increasing these rates by delaying the second dose against the risks associated with the remaining uncertainty in this strategy,” said Thomas C, an assistant professor of medicine. Write by researchers including Kingsley. Mayo Clinic, Minnesota.

“These results should be continuously evaluated as new data become available,” the researchers added.

The Pfizer and Moderna Govit-19 vaccines in a standard two-dose schedule are highly effective in preventing symptomatic infections and death. But because vaccination rates are low, immunity is low worldwide.

The longer it takes for people worldwide to be effectively vaccinated, the greater the risk of developing anti-vaccine strains. This led to calls for as many people as possible to prioritize a single dose of the vaccine, even if it would delay the second dose beyond the time frame studied.

“The justification for this depends on the assumption that meaningful protection against COVID-19 can be achieved after a single dose of vaccine, but this is subject to serious debate,” the panel said.

To further explore this, they set out to measure the impact of delayed second-dose vaccination policies on infections, hospital admissions, and deaths compared to the current schedule two dose regimens. Using a simulation model based on the “real-world” sample population of 100,000 American adults, the group directed a series of sequences over a six-month period.

Results suggest that if vaccine efficacy from a single dose is 80 percent or higher, a delayed second dose strategy may be optimal for vaccination rates of 0.3 percent of the population per day or less.

(The above story first appeared on May 13, 2021 at 01:05 PM IST. For more news and updates on politics, the world, sports, entertainment and lifestyle, log on to our website

Sophia Harrison

Part time worker

I'm Sophia Harrison working as a part-time staff at the Costco since the past year until I become as an author at the iron blade, hope I can use my experiences with the supermarkets here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top